INDIANAPOLIS, May 22, 2021 /PRNewswire/ -- In a pre-specified analysis of the Phase 2 SERENITY study, Eli Lilly and Company's (NYSE: LLY) mirikizumab improved fatigue in patients with moderately ...

Fatigue Tied With Sorafenib, Sunitinib Use in Renal Cell Carcinoma. James Nam, PharmD | January 3, 2018 . Although TKIs improve outcomes, they are still associated with toxicities common ...

The results showed that most patients (72.5%) showed fatigue (mean FACIT-fatigue score 34.8 ± 10.8) and 20% had moderate or severe depression. The Expanded Disability Status Scale (EDSS) score ...

Participants were also asked to complete the 12-item Short-Form survey (SF-12) or the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at baseline.

The improvements in fatigue persisted throughout the 26-week treatment period, and the mean FACIT-Fatigue score was 44.3 at TAT. One patient who missed an infusion reported a FACIT-Fatigue score ...

The goal was to understand how fatigue might influence how patients perceived their memory and thinking during treatment. Cognitive function was measured with the FACT-Cog (CogPCI subscale), and ...

Melatonin showed no benefit for cancer-related fatigue or other symptoms in women with early-stage ... using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue scale).

Bimekizumab Improves Pain, Fatigue in Patients With Active PsA — Health-related quality-of-life scores showed improvements as early as week 4 by Greg Laub , Director, Video, MedPage Today ...

In addition, patients who achieved dactylitis resolution were more likely to demonstrate FACIT-Fatigue response at weeks 24 and 52 (P for both .03), as well as minimal pain at week 24 and ...

No Results. Monday, January 13, 2025 ...